中國TreatyWIPO
2022年2月11日

China Joins Two WIPO Treaties, the Hague System and the Marrakesh Treaty

Snow Pine painted by artist Evelyn Hui, mother of Eagle IP’s founder Dr. Jacqueline Lui

It has been two challenging years, yet there are many reasons to still have hope. We wish you a blessed Lunar New Year as we welcome the year of the Tiger.

We wanted to highlight a few new developments in China.

China has joined the Hague System for the International Registration of Industrial Designs, submitting its instrument of accession to the 1999 Geneva Act of the Hague Agreement on February 5, 2022. The Act will go into effect in China on May 5, 2022.

The Hague System provides a way for designers to file a single international design application to register up to 100 designs in up to 94 countries. This helps applicants save time and money on filing separately applications in each jurisdiction. Applicants don’t need to file a national or regional design application first. They can just directly file an international application in the Hague System in one language with one set of fees.

China joining the Hague System gives international designers the option to obtain design patent rights in China through the streamlined Hague System. Chinese designers likewise will have access to the Hague System and access to streamlined design registration in 90+ countries.

As part of this process, China has been updating its design patent laws to comply with Hague System requirements, most notably increasing design patent protection life from 10 years to 15 years in the newest 4th Amendment of the Patent Law. Full details will be available in May. Please note that Hong Kong and Macau are not included.

On the same day, China also signed onto the Marrakesh Treaty, a humanitarian treaty aimed at removing copyright barriers to providing visual impaired people access to published works. The Marrakesh Treaty was adopted on June 27, 2013 and is also administered by the World Intellectual Property Organization (WIPO). It currently has 84 contracting parties, including China, the US, and the European Union.

Eagle IP are experts in patent law and we offer a one-stop service for your global IP needs.

This article is for general informational purposes only and should not be considered legal advice or a legal opinion on a specific set of facts.

About the Authors

Jennifer Che, J.D. is Vice President and Principal at Eagle IP, a Boutique Patent Firm with offices in Hong Kong, Shenzhen, and Macau.

This article is for general informational purposes only and should not be considered legal advice or a legal opinion on a specific set of facts.

其他文章

AI is magical but NOT magic! Be specific in your AI patents!

2025年1月9日
What is the standard of sufficient disclosure for AI-related patents: A case study in China The rapid growth of AI patent applications present significant challenges to existing patent application and examination practices. One of them is satisfying the requirement for sufficient disclosure. The following case was featured in the 2023 CNIPA Compilation of Key Decisions […]

BREAKING NEWS: New Pilot Program for Hong Kong Applicants to get Accelerated Patent Examination in the Chinese Patent Office Starting January 1, 2023

2023年1月4日
New year, new resolutions! The CNIPA has recently announced a pilot program that provides Hong Kong applicants the opportunity to expedite their patent applications filed in China. Starting 1 Jan 2023, Hong Kong permanent residents and entities legally registered in Hong Kong can request prioritized examination for their invention patent applications before the CNIPA. To […]

How Far Can an Employer Reach to Own Employee-made “Service Inventions”?

2020年7月30日
2019 China’s Top 50 Representative IP Cases Shenzhen Weibang Technology Co. Ltd v. Li Jianyi & Shenzhen Yuancheng Intelligence Equipment Co. Ltd (2019最高法民申6342号) Each year in China there are hundreds of disputes over patent ownership.  A significant part of them are related to “Service Inventions”, which are defined in Article 6 of the Chinese Patent […]

A Stratification Too Far? How the CNIPA Draws the Line on Patient Subgroups in a Recent Precision Medicine Invalidation Case

2026年2月27日
Precision medicine is rapidly transforming the global healthcare landscape, providing more effective therapies and better patient outcomes through targeted solutions. As therapeutics move away from the traditional “one-size-fits-all” model, unique challenges are presented in the patent examination process. The 2024 Top 10 Patent Re-examination and Invalidation case highlighted below provides further insight into how the […]

我們過去活動

Top crossarrow-right